TNSN07240A1 - Compounds for flaviviridae treatment - Google Patents

Compounds for flaviviridae treatment

Info

Publication number
TNSN07240A1
TNSN07240A1 TNP2007000240A TNSN07240A TNSN07240A1 TN SN07240 A1 TNSN07240 A1 TN SN07240A1 TN P2007000240 A TNP2007000240 A TN P2007000240A TN SN07240 A TNSN07240 A TN SN07240A TN SN07240 A1 TNSN07240 A1 TN SN07240A1
Authority
TN
Tunisia
Prior art keywords
flaviviridae
compounds
treatment
flaviviridae treatment
prevention
Prior art date
Application number
TNP2007000240A
Other languages
English (en)
Inventor
Beat Weidmann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TNSN07240A1 publication Critical patent/TNSN07240A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TNP2007000240A 2004-12-23 2007-06-22 Compounds for flaviviridae treatment TNSN07240A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63867604P 2004-12-23 2004-12-23
PCT/US2005/046058 WO2006071618A1 (fr) 2004-12-23 2005-12-20 Composes pour le traitement des infections virales par flaviviridae

Publications (1)

Publication Number Publication Date
TNSN07240A1 true TNSN07240A1 (en) 2008-11-21

Family

ID=36218613

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2007000240A TNSN07240A1 (en) 2004-12-23 2007-06-22 Compounds for flaviviridae treatment

Country Status (17)

Country Link
US (1) US20090214464A1 (fr)
EP (1) EP1830870A1 (fr)
JP (1) JP2008525458A (fr)
KR (1) KR20070089954A (fr)
CN (1) CN101084005A (fr)
AU (1) AU2005322241B2 (fr)
BR (1) BRPI0519355A2 (fr)
CA (1) CA2587586A1 (fr)
IL (1) IL183780A0 (fr)
MA (1) MA29097B1 (fr)
MX (1) MX2007007721A (fr)
NO (1) NO20073765L (fr)
NZ (1) NZ555142A (fr)
RU (1) RU2007128098A (fr)
TN (1) TNSN07240A1 (fr)
WO (1) WO2006071618A1 (fr)
ZA (1) ZA200703907B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
US7754685B2 (en) 2005-09-30 2010-07-13 Scynexis, Inc. Methods and pharmaceutical compositions for the treatment and prevention of hepatitis C infection
ATE498630T1 (de) 2005-09-30 2011-03-15 Scynexis Inc Arylalkyl- und heteroarylalkyl-derivate von cyclosporin a bei der behandlung und vorbeugung einer virusinfektion
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
EP2023918B1 (fr) 2006-05-19 2011-03-23 Scynexis, Inc. Cyclosporines pour le traitement et la prévention de troubles oculaires
US7576057B2 (en) 2006-11-20 2009-08-18 Scynexis, Inc. Cyclic peptides
US9090671B2 (en) 2008-06-06 2015-07-28 Scynexis, Inc. Macrocyclic peptides
WO2010076329A1 (fr) 2008-12-31 2010-07-08 Scynexis, Inc. Dérivés de cyclosporine a
WO2011063076A1 (fr) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Méthodes de traitement du virus de l'hépatite c avec des composés d'oxo-acétamide
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2095926T5 (es) * 1990-11-02 2001-02-16 Novartis Ag Cyclosporins.
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
FR2757521B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757522B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
GB9811854D0 (en) * 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
AR031010A1 (es) * 2000-10-19 2003-09-03 Fujisawa Pharmaceutical Co Una composicion farmaceutica, util para inhibir el dano celular
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
ATE490778T1 (de) * 2004-10-01 2010-12-15 Debiopharm Sa Verwendung von äd-mealaü3-äetvalü4-ciclosporin zur behandlung von hepatitis-c-infektion
EP1830871A1 (fr) * 2004-12-23 2007-09-12 Novartis AG Compositions pour le traitement du vhc

Also Published As

Publication number Publication date
IL183780A0 (en) 2007-09-20
CA2587586A1 (fr) 2006-07-06
US20090214464A1 (en) 2009-08-27
RU2007128098A (ru) 2009-01-27
MA29097B1 (fr) 2007-12-03
AU2005322241A1 (en) 2006-07-06
EP1830870A1 (fr) 2007-09-12
AU2005322241B2 (en) 2010-02-18
NO20073765L (no) 2007-09-19
JP2008525458A (ja) 2008-07-17
CN101084005A (zh) 2007-12-05
WO2006071618A1 (fr) 2006-07-06
ZA200703907B (en) 2009-08-26
NZ555142A (en) 2010-03-26
KR20070089954A (ko) 2007-09-04
MX2007007721A (es) 2007-08-14
BRPI0519355A2 (pt) 2009-01-20

Similar Documents

Publication Publication Date Title
TNSN06071A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
TNSN07240A1 (en) Compounds for flaviviridae treatment
IL257622B (en) Methods and preparations for the treatment of persistent infections
MY139124A (en) Gyrase inhibitors and uses thereof
ZA200701629B (en) Gyrase inhibitors and uses thereof
CL2007002261A1 (es) Compuestos derivados de imidazo[1,2-b]piridazina, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion del cancer.
EP2452935A3 (fr) Dérivés de tétracycline pour le traitement d'infections bactériennes, virales et parasites
WO2006024018A3 (fr) Methodes et compositions pour le traitement de la douleur nociceptive
AP2007004245A0 (en) Compounds and methods for the treatment or prevention of flavivirus infections
TW200630367A (en) Substituted adenines and the uses thereof
SG163517A1 (en) Antiviral compounds and methods
MX2010002318A (es) Derivados azaindol 2,3-sustituidos para tratar infecciones virales.
TW200626157A (en) HCV inhibiting bi-cyclic pyrimidines
DK1419154T3 (da) Rapamycin-29-enoler
MY144318A (en) Methods of treating hiv infection.
MY164469A (en) Hcv ns3 protease inhibitors
TW200716157A (en) Pharmaceutical formulations and methods of treatment using the same
MY145074A (en) Thiazolidin-4-one derivatives
PT2383271E (pt) Aminoquinolonas como inibidores de gsk-3
WO2006116221A3 (fr) Nouvelles combinaisons therapeutiques pour le traitement ou la prevention de troubles psychotiques
WO2007109105A3 (fr) Inhibition des flavivirus par des sultames et composes apparentes
TW200716088A (en) Formulations and methods for treating amyloidosis
TN2009000135A1 (en) Use of modified cyclosporins
SI1838716T1 (sl) Olanzapin pamoat dihidrat
MXPA05010388A (es) Dispositivos, metodos y composiciones para prevenir la restenosis.